HER-2/neuTOP2A/CSP17基因多色检测试剂盒

 广州健仑生物科技​有限公司 

本司长期供应尼古丁（可替宁）检测试剂盒，其主要品牌包括美国NovaBios、广州健仑、广州创仑等进口产品，国产产品，试剂盒的实验方法是胶体金方法。

我司还有很多荧光原位杂交系列检测试剂盒以及各种FISH基因探针和染色体探针等，。

HER-2/neuTOP2A/CSP17基因多色检测试剂盒

欢迎咨询

欢迎咨询

以下是我司出售的部分FISH产品：

我司还提供：登革热，黄热病，基肯孔热，西尼罗河，立次克体，无形体，蜱虫，恙虫，锥虫，利什曼原虫，RK39, 汉坦病毒，乙脑，森林脑炎，寨卡病毒 ，H7N9 ,流感，霍乱，军团菌，结核，诺如病毒，轮状病毒，炭疽，O157，葡萄球菌 ，流行性出血热，伤寒杆菌，志贺氏菌检测试剂,！

二维码扫一扫

【公司名称】 广州健仑生物科技有限公司
【】    杨永汉 

【】
【腾讯 】
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室

【企业文化宣传】

In the ten major scientific breakthroughs of 2017, the "precise location of gene editing" was listed on the list. For this reason, a famous American consulting company recently released a report that the market size of global genome editors, including CRISPR, TALEN and ZFN, will increase from 3 billion 190 million US dollars in 2017 to 6 billion 280 million US dollars in 2022, with a compound annual growth rate of 14.5%.

The technology of gene editing is commonly known as gene scissors. Whether the prediction of the scissors market cake of American consulting company is accurate or not needs to be tested in the future market. However, from theoretical analysis and prediction, we need to first see the entry threshold of the three gene scissors, including the acceptance of the public, and whether the professional and administrative organs approve.

The main market applications of gene scissors include cell line transformation, genetic engineering, diagnosis and treatment of diseases. At present, the transformation of cell lines is the largest share, and the research of gene editing stem cell therapy is highly recognized.

As far as public and market acceptance is concerned, the lowest threshold for gene scissors and the easiest area to enter is crop improvement, and it is also easily approved. Even if gene scissors are inaccurate, it may cause adverse consequences, but because it is improvement of crops instead of humans, it will not cause direct harm to humans and too many disasters.

Although the market share of gene scissors for disease control is very large, the threshold of market entry is particularly high. The main reason is that the gene scissors need to ensure the safety of the technology and the ethical review and approval of the health management department. As a gene scissors, CRISPR is highly efficient, but its accuracy is doubtful. Therefore, the application of gene scissors has been questioned and opposed by some biomedical experts.

In September 2017, the Oregon Health and Science University's Mitalipov team published a hypertrophic cardiomyopathy caused by CRISPR-Cas9 gene scissors cut off embryos (HCM) of the MYBPC3 gene mutation, called the experimental group in 58 subjects embryos, 42 embryos did not carry pathogenic gene mutation in patients with hypertrophic cardiomyopathy, accounted for more than 74.2%. If the gene is not processed, the normal probability of the fertilized egg is 50% when the 50% spermatozoon is normal. That is to say, the proportion of the compley normal embryos increased from 50% to 74.2% by gene editing, which may eliminate the etiology of hypertrophic cardiomyopathy from the embryo.